https://www.mithra.com/wp-content/uploads/2017/03/CP-02-03-17.jpg 713 1030 Mithra Pharmaceuticals https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Mithra Pharmaceuticals2017-03-01 18:00:012020-07-03 11:50:36Mithra Signs a Binding Term Sheet with the Japanese Leader in Women’s Health Fuji Pharma to Commercialize Donesta® in Japan and ASEAN
- Mithra signs a binding term sheet for Donesta® with Fuji Pharma, in line with its strategy to partner out its lead Estetrol-based products
- Fuji Pharma, the Women’s Health leader in Japan, obtains the rights to commercialize Donesta®, Mithra’s Hormonal Treatment (HT) product candidate based on Estetrol, in Japan and ASEAN. Fuji Pharma intend to extend the actual market of menopause in Japan which represents EUR 42.6 million, thanks to the potential advantages of Estetrol use in menopause.
- The 20-year partnership agreement, which includes an exclusive supply agreement by Mithra’s CDMO, should generate single-digit upfront milestones. More details on the deal will be communicated when the full and complete LSA is finalized.
- Mithra also provides an update on its Phase II program for Donesta®. Following discussions with the regulatory agencies and recommendations of its international scientific committees, Mithra has decided to extend the protocol of its Phase II study, and top line results are now expected in Q1 2018.
- Mithra will accelerate its business development efforts for Donesta®, and plans to identify global partners its Phase III program, as it now does with Fuji.
- The term sheet with Fuji underlines the strategy adopted, while also demonstrating the value of the reinforced Phase II study for the further development and commercialization of Donesta®.